Bio-business in brief: the case for ambitious action in the public sector

被引:0
|
作者
VijayRaghavan, K. [1 ]
Saberwal, Gayatri [2 ]
机构
[1] Govt India, Dept Biotechnol, Block 2,7th Floor,CGO Complex,Lodi Rd, New Delhi 110003, India
[2] Inst Bioinformat & Appl Biotechnol, Biotech Pk,Elect City Phase 1, Bengaluru 560100, India
来源
CURRENT SCIENCE | 2017年 / 113卷 / 10期
关键词
Basic research; biotech industry; liberalization; pharma industry; public sector; INDIA;
D O I
10.18520/cs/v113/i10/1841-1845
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
At the time of independence, India was a poor country. Nevertheless, the Government saw fit to invest in industry and research. In recent decades the public sector has received a bad press, with pressure to reduce it while increasing the role of the private sector. The public sector is not intrinsically bad, but has often been misused. The 'market' and the ` state' each have a role in economic development. To ensure steady growth of the economy, the country must ensure universal healthcare, for which it needs an innovative homegrown industry and universal good education. This requires large public investment.
引用
收藏
页码:1841 / 1845
页数:5
相关论文
共 50 条
  • [1] Bio-business in brief: the case of conotoxins
    Mehdiratta, Ritu
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2007, 92 (01): : 39 - 45
  • [2] Bio-business in brief: The case of Cytokinetics Inc.
    #H1/5, H1 Block, 1st Main Road, Thiruvalluvar Nagar, Thriuvanmiyur, Chennai 600 041, India
    不详
    不详
    [J]. Curr. Sci., 2008, 12 (1576-1581):
  • [3] Bio-business in brief: The case of Cytokinetics Inc.
    Devaguptapu, Sailaja
    Mehdiratta, Ritu
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2008, 94 (12): : 1576 - 1581
  • [4] Bio-business in brief: Many a monoclonal
    NEN Wadhwani Centre for Excellence in Entrepreneurship Education, Institute of Bioinformatics and Applied Biotechnology, G-05, Tech. Park Mall, Whitefield Road, Bangalore 560 066, India
    [J]. Curr. Sci., 2007, 6 (789-796):
  • [5] Bio-business in brief: Many a monoclonal
    Mehdiratta, Ritu
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2007, 93 (06): : 789 - 796
  • [6] Bio-business in brief: The challenges of clinical trials
    Mehdiratta, Ritu
    Parida, Deepak Kumar
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2007, 93 (10): : 1367 - 1375
  • [7] Bio-business in brief: the debate over biosimilars
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2010, 98 (12): : 1575 - 1578
  • [8] Bio-business in brief: a bit about technology transfer
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2010, 99 (02): : 177 - 180
  • [9] Bio-business in brief: the paradox of being a drug company
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2009, 97 (05): : 622 - 624
  • [10] Bio-business in brief: a case for new drugs at generic prices from India
    Venkatachalam, Suri
    Saberwal, Gayatri
    [J]. CURRENT SCIENCE, 2012, 102 (10): : 1375 - 1381